Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

Astria Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

-- ALPHA-STAR Phase 1b/2 Trial Initial Proof-of-Concept Results Support Potential for STAR-0215 to Become the Market Leader in HAE with Q3M and Q6M Administration --

-- Preclinical Results for STAR-0310, Potential Best-in-Class OX40 Program for the Treatment of Atopic Dermatitis, to be Shared at Upcoming Society for Investigative Dermatology Conference --

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the first quarter ended March 31, 2024, and provided a corporate update.

"We are thrilled with the ALPHA-STAR initial proof-of-concept results that we shared in March, and believe that STAR-0215 can be a life-changing therapy for people living with HAE," said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. "The efficacy we have seen to date, along with the favorable safety and tolerability profile with no injection pain observed, support the ability to administer STAR-0215 every three and every six months and give us confidence that we are developing a therapy that has the potential to lead the HAE market. We are progressing to a pivotal Phase 3 trial, expected to initiate in Q1 2025 for our Q3M regimen. Our plans are to develop a Q3M regimen first to take the fastest path to market, and then to rapidly expand the label with Q6M administration to further reduce the treatment burden for people with HAE."

STAR-0215

  • The Company shared positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial of STAR-0215 in people with hereditary angioedema (HAE) in March 2024. STAR-0215 dosed once or twice over six months reduced monthly attack rates by 90-96% and supports chronic dosing two or four times per year. The trial saw a 92-100% decrease in moderate or severe attacks and a 91-95% reduction in attacks requiring rescue medications with STAR-0215. Additionally, STAR-0215 was very well-tolerated with no serious adverse events and no discontinuations. Initial pharmacodynamic data show strong, durable, and clinically-relevant inhibition of plasma kallikrein through up to six months after one or two doses. Initial pharmacokinetic data are consistent with modeling developed from the Phase 1a data. The Company plans to report additional data from ALPHA-STAR in the second half of 2024.
  • Based on the positive results from the ALPHA-STAR trial, Astria plans to advance STAR-0215 to Phase 3 development. To progress STAR-0215 to market as quickly as possible, the Company plans to start the Phase 3 program with Q3M dosing, with trial initiation expected in Q1 2025 and top-line results expected by year-end 2026. The company believes STAR-0215 Q3M dosing will be life-changing for HAE patients, the fastest path to market, and help to establish STAR-0215 as the market leader in HAE. Following the enrollment of the Q3M Phase 3 trial, the Company plans to initiate a Q6M Phase 3 trial to support label expansion with the goal of further solidifying STAR-0215's leadership position in the HAE market.
  • After completion of the ALPHA-STAR trial, patients have the opportunity to continue to receive STAR-0215 every three or six months in the long-term open-label Phase 2 ALPHA-SOLAR trial. Initial safety and efficacy data from ALPHA-SOLAR, including from Q3M and Q6M administration, are expected mid-2025.

STAR-0310

  • Astria is developing STAR-0310, a high affinity monoclonal antibody OX40 antagonist that incorporates YTE technology, for the treatment of atopic dermatitis (AD).
  • STAR-0310, a preclinical stage program, has the potential to have the best-in-class profile in AD. Astria is on track to submit an Investigational New Drug (IND) application for STAR-0310 by year-end 2024 and plans to initiate a Phase 1a clinical trial in healthy subjects in the first quarter of 2025, with initial results from the trial expected in the third quarter of 2025.
  • Astria will present a poster titled, "Preclinical Profile of STAR-0310, a Novel OX40 Antagonistic Monoclonal Antibody" at the Society for Investigative Dermatology (SID) Annual Meeting in Dallas, Texas. The poster will be available during Session One of the Pharmacology and Therapeutic Development Select E-Poster Discussions on May 16, 2024 at 5:00pm CST.

Corporate Updates

  • Astria recently published its inaugural Corporate Social Responsibility (CSR) Report. The 2023 report provides a comprehensive update on the Company's performance and progress across key Environmental, Social, and Governance (ESG) areas of focus. To learn more about Astria's CSR initiatives, please view the full report at this link: https://ir.astriatx.com/corporate-social-responsibility .
  • Astria appointed Sunil Agarwal, M.D., to its Board of Directors. Dr. Agarwal has more than 20 years of biotechnology research, development, and commercialization experience.

First Quarter 2024 Financial Results

Cash Position: As of March 31, 2024, Astria had cash, cash equivalents and short-term investments of $369.9 million, compared to $246.5 million as of December 31, 2023. The Company expects that its cash, cash equivalents and short-term investments as of March 31, 2024 will be sufficient to fund its operations into mid-2027, including all STAR-0215 program activities through the completion of a planned Q3M Phase 3 pivotal trial as well as advancing the STAR-0310 OX40 program through submission of an IND and early proof-of-concept results from a Phase 1a clinical trial. Net cash used in operating activities for the three months ended March 31, 2024 was $19.1 million, compared to $13.3 million for the three months ended March 31, 2023.

R&D Expenses: Research and development expenses were $15.7 million for the three months ended March 31, 2024, compared to $8.0 million for the three months ended March 31, 2023. The increase in research and development expenses was primarily associated with our STAR-0215 program's advancement in our multi-site international clinical trials in addition to external research and development costs associated with our STAR-0310 program including manufacturing and IND-enabling activities.

G&A Expenses: General and administrative expenses were $8.4 million for the three months ended March 31, 2024, compared to $5.5 million for the three months ended March 31, 2023. The increase in general and administrative expenses was primarily attributable to company growth and supporting activities for the advancement of our programs.

Operating Loss: Loss from operations was $24.2 million for the three months ended March 31, 2024, compared to $13.5 million for the three months ended March 31, 2023.

Net Loss: Net loss was $19.9 million for the three months ended March 31, 2024, compared to a net loss of $11.2 million for the three months ended March 31, 2023.

Net Loss Per Share Basic and Diluted: Net loss per share basic and diluted was $0.38 for the three months ended March 31, 2024, compared to a net loss basic and diluted of $0.40 per share for the three months ended March 31, 2023.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com , or follow us on X and Instagram @AstriaTx and on Facebook and LinkedIn.

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the initial results from the Phase 1b/2 ALPHA-STAR clinical trial of STAR-0215, and that the results from such trial will allow us to move directly into a Phase 3 trial of STAR-0215 as a potential treatment for hereditary angioedema (HAE); the expected timing of the release of additional data from the ALPHA-STAR trial; the expected timing of initiation and design of the planned Phase 3 trials of STAR-0215; the expected timing of release of the safety and efficacy data from the ALPHA-SOLAR trial; the potential for STAR-0215 in the HAE market, including to be the market leader, and to have the best-in-class profile in HAE, the potential therapeutic benefits of STAR-0215 as a treatment for HAE and our vision and goals for the program; the potential for STAR-0310 to have the best-in-class profile in AD and the potential therapeutic benefits and potential attributes of STAR-0310 as a treatment for AD; expectations regarding the timing of regulatory filings for STAR-0310; expectations regarding the timing of initiation and planned design of clinical trials for STAR-0310; the expectations regarding the timing and nature of anticipated data for planned trials of STAR-0310; our goals and vision for STAR-0310; anticipated cash runway; and the goal to meet the unmet needs of patients with rare and niche allergic and immunological diseases. The use of words such as, but not limited to, "anticipate," "believe," "continue," "could," "estimate," "expect," "goals," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," "would," or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the following risks and uncertainties: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be replicated in clinical trials, that the preliminary or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the Phase 1a clinical trial, may not be replicated in later stage clinical trials, including the ALPHA-STAR trial, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the U.S. Food and Drug Administration and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to STAR-0215, STAR-0310, and any other future development candidates; our ability to manufacture sufficient quantities of drug substance and drug product for STAR-0215, STAR-0310, and any other future product candidates on a cost-effective and timely basis, and to develop dosages and formulation for STAR-0215, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefore; our ability to obtain, maintain and enforce intellectual property rights for STAR-0215, STAR-0310, and any other future product candidates; our potential dependence on collaboration partners; competition with respect to STAR-0215, STAR-0310, or any of our other future product candidates; the risk that survey results and market research may not be accurate predictors of the commercial landscape for HAE, the ability of STAR-0215 to compete in HAE and the anticipated position and attributes of STAR-0215 in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks that any of our clinical trials of STAR-0310 may not commence, continue or be completed on time, or at all; risks that results of preclinical studies of STAR-0310 will not be replicated in clinical trials; risks with respect to the ability of STAR-0310 to compete in AD and the anticipated position and attributes of STAR-0310 in AD based on its preclinical profile; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the period ended December 31, 2023 and in other filings that we may make with the Securities and Exchange Commission.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof.

Astria Therapeutics, Inc.
  Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)

Three Months Ended March 31,

2024

2023

Operating expenses:
Research and development

$

15,726

$

8,033

General and administrative

8,424

5,460

Total operating expenses

24,150

13,493

Loss from operations

(24,150

)

(13,493

)

Other income (expense):
Interest and investment income

4,241

2,321

Other expense, net

(19

)

(16

)

Total other income, net

4,222

2,305

Net loss

(19,928

)

(11,188

)

Net loss per share attributable to common shareholders - basic and diluted

$

(0.38

)

$

(0.40

)

Weighted-average common shares outstanding used in net loss per share - basic and diluted

52,294,765

27,944,458

Astria Therapeutics, Inc.
  Selected Consolidated Balance Sheets Data
(In thousands)
(Unaudited)

March 31, December 31,

2024

2023

Assets
Cash and cash equivalents

$

172,012

$

175,530

Short-term investments

197,895

71,000

Right-of-use asset

210

363

Other current and long-term assets

8,690

7,773

Total assets

378,807

254,666

Liabilities and stockholders' equity
Current portion of operating lease liabilities

168

329

Other current and long-term liabilities

10,904

11,221

Total liabilities

11,072

11,550

Total stockholders' equity

$

367,735

$

243,116

Astria Therapeutics, Inc.
  Selected Consolidated Statements of Cash Flows Data
(In thousands)
(Unaudited)

Three Months Ended March 31,

2024

2023

Net cash used in operating activities

$

(19,094

)

$

(13,253

)

Net cash (used in) provided by investing activities

(126,231

)

194,992

Net cash provided by financing activities

141,807

37

Net (decrease) increase in cash, cash equivalents and restricted cash

$

(3,518

)

$

181,776

Investor Relations and Media:  
Elizabeth Higgins
investors@astriatx.com

News Provided by Business Wire via QuoteMedia

ATXS:US
The Conversation (0)
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Healthcare Conference on Thursday, June 6 th at 10:00am ET in New York, NY.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff302/atxs/1868288 . An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics to Present at Upcoming Eastern Allergy Conference

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final STAR-0215 Phase 1a healthy subject data in an encore presentation at the upcoming Eastern Allergy Conference in Palm Beach, Florida on June 1, 2024.

Jessica Best, Vice President of Medical Affairs at Astria Therapeutics, will present a poster titled, "Updated Results of a Phase 1a Trial of STAR-0215 for Hereditary Angioedema" at 9:45am EST on Saturday, June 1.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics to Present at Upcoming European Academy of Allergy and Clinical Immunology Congress

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present two posters at the upcoming European Academy of Allergy and Clinical Immunology (EAACI) Congress in Valencia, Spain on June 1, 2024.

  • Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité Universitätsmedizin in Berlin, will present information on ALPHA-SOLAR, a long-term open-label trial of STAR-0215 in people living with HAE, in a poster titled "Rationale and Design of the ALPHA-SOLAR Clinical Trial of STAR-0215 for the Treatment of Hereditary Angioedema (HAE)." The poster session will take place on Saturday, June 1 at 12:00pm CEST.
  • Nikos Biris, Ph.D., Senior Director of Assay Development at Astria Therapeutics, will present information on the characterization of STAR-0310 in a poster titled "Development and Characterization of STAR-0310: a Novel OX40 Antagonistic Monoclonal Antibody." The poster session will take place on Saturday, June 1 at 12:00pm CEST.

About Astria Therapeutics:

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 173,500 shares of Astria's common stock on May 1, 2024 under Astria's 2022 Inducement Stock Incentive Plan. The 2022 Inducement Stock Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of Astria.

The options were granted as an inducement material to four employees entering into employment with Astria in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $9.50 which is equal to the closing price of Astria's common stock on May 1, 2024 (the "Grant Date"), and will vest over a four-year period, with 25% of shares vesting on the first anniversary of the employee's employment start date (which preceded the Grant Date) and the remaining shares vesting monthly on a ratable basis over the following 36 months, subject to the employee's continued employment with Astria on such vesting dates. The options are subject to the terms and conditions of the 2022 Inducement Stock Incentive Plan and the terms and conditions of an award agreement covering the grant.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West

Noble Mineral highlights Successful Exploration Results announced by Canada Nickel, including Highest Grade to Date at Mann West

(TheNewswire)

Noble Mineral Exploration Inc.

TORONTO TheNewswire - March 13, 2025 Noble Mineral Exploration Inc. ("Noble" or the "Company") (TSXV: NOB) (OTCQB: NLPXF) is pleased to announce successful exploration drilling results from its joint venture partner Canada Nickel Company Inc. ("Canada Nickel") (TSXV:CNC) in East Timmins Nickel Ltd. ("East Timmins Nickel") a private company operating in the Timmins area of Northern Ontario.

News Provided by TheNewsWire via QuoteMedia

Keep reading...Show less
Global Nickel Mining Market Size Forecasted to Reach $100 Billion By 2034 as Demand for Electric Vehicles Rises

Global Nickel Mining Market Size Forecasted to Reach $100 Billion By 2034 as Demand for Electric Vehicles Rises

FN Media Group News Commentary - The mining industry's increasing focus on sustainability and responsible practices is influencing nickel mining. Companies are adopting environmentally friendly processes to meet regulatory standards and consumer expectations. According to a recent report from Precedence Research said: "The global nickel mining market size is calculated at USD 56.42 billion in 2025 and is forecasted to reach around USD 100.29 billion by 2034, accelerating at a CAGR of 6.56% from 2025 to 2034. The Asia Pacific market size surpassed USD 30.81 billion in 2024 and is expanding at a CAGR of 6.65% during the forecast period. The market sizing and forecasts are revenue-based (USD MillionBillion), with 2024 as the base year. The global nickel mining market size accounted for USD 53.12 billion in 2024 and is predicted to increase from USD 56.42 billion in 2025 to approximately USD 100.29 billion by 2034, expanding at a CAGR of 6.56% from 2025 to 2034." It continued: "North America is set for swift expansion in the nickel mining market owing to a heightened need for nickel in electric vehicle (EV) manufacturing and renewable energy applications. The region's commitment to clean energy initiatives and carbon reduction fuels the demand for nickel, essential in EV battery production. Supported by favorable government policies, investments in sustainable mining methods, and advancements in mining technologies, North America stands as a pivotal player in the growing nickel mining sector on the global stage. The rapid expansion of the electric vehicle (EV) market stands as a pivotal catalyst, driving a surge in nickel demand. Nickel's indispensable role in electric vehicle batteries positions it as a cornerstone element in this burgeoning market. Projections from the International Energy Agency (IEA) indicate a noteworthy 41% increase in global electric car sales, surpassing 3 million units in 2020, underscoring the heightened nickel consumption associated with the EV boom."   Active Companies mentioned in the article includes: First Atlantic Nickel Corp. (OTCQB: FANCF) (TSX-V: FAN), TMC the metals company Inc. (NASDAQ: TMC), Tesla, Inc. (NASDAQ: TSLA), FPX Nickel Corp. (OTCQB: FPOCF) (TSX-V: FPX), Power Metallic Mines Inc. (OTCBB: PNPNF) (TSX-V: PNPN).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Red Metal Resources Commences Sampling and Mapping Program on its Carrizal IOCG Property

Red Metal Resources Commences Sampling and Mapping Program on its Carrizal IOCG Property

Red Metal Resources Ltd. (CSE: RMES) (OTC Pink: RMESF) (FSE: I660) ("Red Metal" or the "Company")  is pleased to announce it has now commenced an extensive sampling and mapping work program to follow-up on and extend previously identified veins that make up approximately 15km of veining extending along strike from the historic Carrizal Alto mine.

This active 2025 work program will continue work delineating the vast vein system on Carrizal property and aid in refining future drill targets. All samples will be sent for assay and the Company expects a steady stream of assay results shortly.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Vertex Minerals Limited  Key Operational Personnel added to Execute Reward High Grade

Vertex Minerals Limited Key Operational Personnel added to Execute Reward High Grade

Perth, Australia (ABN Newswire) - Vertex Minerals Limited (ASX:VTX) (OTCMKTS:VTXXF) is pleased to announce seven key operational appointments to progress the Company's operational plans for the high grade Reward Underground Gold Mine.

Alan Mills, Commercial Manager - Alan is a qualified chartered accountant with over 15 years' experience. He has worked for multinational and ASX listed mining organisations such as Glencore, Aeris Resources, Newmont Corporation and Mitsui in site and corporate senior commercial, financial and management accounting roles.

Alan holds a Bachelor of Commerce (Accounting) from Griffith University and is a member of Chartered Accountants Australia and New Zealand.

Thomas Cowan, Senior Mining Engineer - Thomas holds a B. Eng (Mining) from University of Wollongong, a Grad. Dip of Mine Ventilation and a NSW Underground Supervisors certificate. He is experienced in mine planning, drill and blast, and ventilation in both underground coal and base metals. Tom recently worked at Aeris Resources Tritton mine.

Carl Clark, Senior Mining Geologist - "Vertex holds one of the premier gold resources of NSW at Hill End. I'm excited to be part of the team to re-awaken this Australian gold mining icon". Carl has 30+ years' experience as a geologist internationally and in Australia where he cut teeth in the WA goldfields.

Julian Geldard, Senior Mining Geologist - With nearly a decade of experience in mining and exploration in various commodities, Julian has a high focus on narrow vein gold within the Lachlan fold belt. He recently worked as a Project Geologist at Ballarat Goldfields and Woods Point Gold Mine.

Dennis Fernandez, Underground Shift Boss - An underground mining veteran of 34 years, including 14 years of airleg experience, Dennis bring a wealth of knowledge and experience in narrow vein underground gold mining.

Dennis holds underground supervisor tickets for both NSW and Western Australia and was most recently employed at Tritton Operations.

Mick Irwin, Safety and Training Superintendent - Mick started with Vertex Minerals in early January 2025 after more than 20 years in the underground coal mining industry. The Reward Gold Mine project has been a massive shift in his professional and personal life, which he and his family see as move to greater things. Mick is looking forward to the opportunity of working with Vertex to develop the Reward Underground Mine.

Casey Robinson Environmental Advisor - Casey graduated from the University of Wollongong in November 2024 with a Degree in Environmental Engineering, before Starting at Vertex as Environmental Advisor in December. He is looking forward to beginning his career in the mining industry with Vertex.

Executive Chairman, Roger Jackson, said:

"We have secured a further seven outstanding senior personnel to direct our mining operations. With decades of experience, they add to the growing, dynamic Vertex team. We are rapidly advancing our operational readiness to meet the challenges of commencing mining at the Reward Gold Mine.. We are delighted to welcome Alan, Tom, Casey, Dennis, Julian, Mick and Carl to the Vertex team, leveraging their strong skills and experience".



About Vertex Minerals Limited:  

Vertex Minerals Limited (ASX:VTX) is an Australian based gold exploration company developing its advanced Hargraves and Hill End gold projects located in the highly prospective Eastern Lachlan Fold Belt of Central West NSW. Other Company assets include the Pride of Elvire gold project and Taylors Rock gold/nickel/lithium project both located in the Eastern Goldfields of WA. The focus of Vertex Minerals is to advance the commercial production of gold from its NSW projects embracing an ethical and environmentally sustainable approach.



Source:
Vertex Minerals Limited

News Provided by ABN Newswire via QuoteMedia

Keep reading...Show less
Silver47 Closes Additional Tranche of Non-Brokered Private Placement

Silver47 Closes Additional Tranche of Non-Brokered Private Placement

Silver47 Exploration Corp. (TSXV: AGA) ("Silver47" or the "Company") is pleased to announce the closing of an additional tranche (the "Additional Tranche") of its previously announced non-brokered private placement (the "Private Placement") (as set out in the Company's news releases dated February 19 and 24, 2025). Pursuant to the closing of the Additional Tranche, the Company issued 4,155,000 units of the Company (the "Units") at a price of $0.50 each for aggregate gross proceeds to the Company of $2,077,500. The Company anticipates completing the balance of the Private Placement on or around March 19, 2025 or as may be determined by the Company.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Anteros Advances Critical Mineral Targeting with AI-Assisted 3D Modelling at their Havens Steady VMS Property, Newfoundland

Anteros Advances Critical Mineral Targeting with AI-Assisted 3D Modelling at their Havens Steady VMS Property, Newfoundland

 Anteros Metals Inc. (CSE: ANT) ("Anteros" or the "Company") is excited to announce integration of advanced AI-assisted geochemical and lithological analysis into the 3D modelling of its Havens Steady Critical Mineral VMS Property (the "Property"), located near Buchans, Newfoundland. This innovative approach detects geochemical anomalies through AI-assisted K-means clustering, while enhancing deposit understanding by correlating mineralization with documented lithological units and alteration attributes. With additional modelling incorporating surficial data expected by the end of March, Anteros is poised to further refine and optimize its 2025 exploration program to prioritize high-potential drill targets.

AI-ASSISTED MODELLING HIGHLIGHTS

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×